APY0201

• CAT Number: I013840
• CAS Number: 1232221-74-7
• Molecular Formula: C₂₃H₂₃N₇O
• Molecular Weight: 413.48
• Purity: ≥95%
• Target: Interleukin RelatedPIKfyve
• Solubility: DMSO: ≥ 35 mg/mL
• IUPAC Name: N-[(E)-(3-methylphenyl)methylideneamino]-7-morpholin-4-yl-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-5-amine
• InChI: InChI=1S/C23H23N7O/c1-17-3-2-4-18(13-17)16-25-27-21-15-23(29-9-11-31-12-10-29)30-22(26-21)14-20(28-30)19-5-7-24-8-6-19/h2-8,13-16H,9-12H2,1H3,(H,26,27)/b25-16+
• InChIKey: RFZQYGBLRIKROZ-PCLIKHOPSA-N
• SMILES: CC1=CC(=CC=C1)/C=N/NC2=NC3=CC(=NN3C(=C2)N4CCOCC4)C5=CC=NC=C5

APY0201（Cat No.:I013840）is an experimental small molecule being developed for its potential therapeutic applications, primarily in the field of immuno-oncology. It is designed to target and modulate immune checkpoint pathways, particularly those involved in the regulation of T-cell responses. By inhibiting certain immune checkpoint proteins, APY0201 aims to enhance the body’s immune response against cancer cells. This mechanism has potential applications in treating various cancers, including solid tumors and hematologic malignancies. Clinical trials are ongoing to assess its safety, efficacy, pharmacokinetics, and ability to improve cancer treatment outcomes when combined with other immunotherapies.

Reference

[1]. Hayakawa N, et al. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201. Bioorg Med Chem. 2014 Jun 1;22(11):3021-9.